Elisrasib

• Description:

  Elisrasib is an orally active inhibitor for KRAS. Elisrasib inhibits the proliferation of KRASG12C mutant H358 and MIA-PA-CA-2 with an IC50 of 0.6 and 0.44 nM. Elisrasib exhibits good metabolic stability in hepatocytes, liver microsomes, plasma and whole blood in various species. D3S-001 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice[1].

• Product Name Alternative:

  D3S-001

• UNSPSC:

  12352005

• Target:

  Ras

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/d3s-001.html

• Purity:

  98.50

• Smiles:

  FC(F)(F)C(C(C)=CC(N)=C1F)=C1[C@@H]2CC3=NC(OC[C@@]45N(CCC5)C[C@@H](C4)F)=NC(N6C[C@@H](N(CC6)C(C(F)=C)=O)CC#N)=C3CO2

• Molecular Formula:

  C32H35F6N7O3

• Molecular Weight:

  679.66

• References & Citations:

  [1]Xu Y, et al., Crystal form of pyrimidine heterocyclic compound and preparation method therefor. WO2023036282.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [2914919-85-8]